456-46-2

Usage

Uses

Used in Pharmaceutical Research and Development:
3-(FluoroMethyl)aniline is used as a key building block in the synthesis of various pharmaceuticals, contributing to the development of new drugs and therapeutic agents. Its unique structure allows for the creation of molecules with specific properties, making it a valuable component in medicinal chemistry.
Used in Agrochemical Production:
In the agrochemical industry, 3-(FluoroMethyl)aniline serves as an essential intermediate for the production of various agrochemicals. Its incorporation into these compounds can enhance their effectiveness in agricultural applications, such as pest control and crop protection.
Used in Dye and Pigment Manufacturing:
3-(FluoroMethyl)aniline is utilized as an intermediate in the manufacture of dyes and pigments, providing a range of color options and properties for various industries. Its presence in these compounds can improve their stability, color intensity, and resistance to fading.
Used in Fine Chemicals Production:
As an intermediate in the production of fine chemicals, 3-(FluoroMethyl)aniline contributes to the development of specialty chemicals used in a wide range of applications, from fragrances and flavorings to advanced materials and coatings. Its versatility and reactivity make it a valuable component in the synthesis of these high-value products.

Upstream product

• 455-94-7 1-(fluoromethyl)-3-nitrobenzene 
• 619-25-0 3-Nitrobenzyl alcohol 

Relevant academic research and scientific papers

Identification of Diarylurea Inhibitors of the Cardiac-Specific Kinase TNNI3K by Designing Selectivity against VEGFR2, p38α, and B-Raf

A series of diarylurea inhibitors of the cardiac-specific kinase TNNI3K were developed to elucidate the biological function of TNNI3K and evaluate TNNI3K as a therapeutic target for the treatment of cardiovascular diseases. Utilizing a structure-based design, enhancements in kinase selectivity were engineered into the series, capitalizing on the established X-ray crystal structures of TNNI3K, VEGFR2, p38α, and B-Raf. Our efforts culminated in the discovery of an in vivo tool compound 47 (GSK329), which exhibited desirable TNNI3K potency and rat pharmacokinetic properties as well as promising kinase selectivity against VEGFR2 (40-fold), p38α (80-fold), and B-Raf (>200-fold). Compound 47 demonstrated positive cardioprotective outcomes in a mouse model of ischemia/reperfusion cardiac injury, indicating that optimized exemplars from this series, such as 47, are favorable leads for discovering novel medicines for cardiac diseases.

HEPATITIS B ANTIVIRAL AGENTS

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

REACTIONS OF NITRO ALCOHOLS WITH N,N-DIETHYL-1,1,2,3,3,3-HEHAXFUOROPROPYLAMINE

Fluorination of nitro alcohols with N,N-diethyl-1,1,2,3,3,3-hexafluoropropylamine (PPDA) was investigated. 3-Nitrobenzyl fluoride (II) was obtained from the reaction of PPDA and 3-nitrobenzyl alcohol (I) (yield 66 percent).The reaction of 2-methyl-2-nitro